Anti-clotting treatment apixaban outperforms Lovenox in study

03/4/2010 | Reuters

Apixaban beat standard treatment Lovenox in preventing blood clots without increasing the risk of bleeding during a late-stage trial in patients who underwent knee surgery. Apixaban is a product of Pfizer and Bristol-Myers Squibb, which plan to submit the drug for European approval this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA